MRK · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
Merck & Co., Inc. · 2026-08-07 · Importance 49 · Surprise 32 · No source text
Worldwide sales increased 5% year over year to $16.6 billion in the second quarter of 2026 and to $32.9 billion in the first six months of 2026. U.S. sales rose to $9.4 billion in the quarter and $18.5 billion year to date, while international sales reached $7.2 billion and $14.4 billion, respectively. Oncology growth was led by Keytruda/Keytruda Qlex sales of $8.4 billion in the quarter and $16.4 billion year to date, while Welireg sales increased 67% and 57% in the respective periods. Cardiometabolic and respiratory growth reflected Winrevair sales increases of 75% and 81%, whereas diabetes sales declined 31% and 29% because of Januvia and Janumet competition and pricing pressure. Animal Health sales increased 8% in the quarter and 10% year to date to $1.8 billion and $3.6 billion, while vaccines declined year to date, including a 9% decline in Gardasil/Gardasil 9 sales to $2.2 billion.
Key facts
- Worldwide sales were $16.6 billion and $32.9 billion in the second quarter and first six months of 2026, representing increases of 5% compared with the same periods of 2025. source
- Sales of Gardasil/Gardasil 9 were $1,169 million in the three months ended June 30, 2026 and $2,238 million in the six months ended June 30, 2026, with combined worldwide sales growing 4% in Q2 2026 and declining 9% in the first six months of 2026. source
- Welireg sales rose 67% and 57% in the second quarter and first six months of 2026, respectively. source
- Winrevair sales rose 75% and 81% in the second quarter and first six months of 2026, respectively, largely due to continued uptake in the U.S. and early launch uptake in Japan and Europe. source
- Vaxneuvance worldwide sales declined 35% and 24% in the second quarter and first six months of 2026, respectively, primarily due to $60 million of favorable CDC stockpile activity in the U.S. in the prior year and lower demand. source
- Prevymis worldwide sales grew 29% and 30% in the second quarter and first six months of 2026, respectively, primarily due to higher demand in the U.S. and certain European markets reflecting the launch of new indications. source
- The year-to-date Keytruda period in 2026 reflects an approximate $250 million favorable impact due to the timing of wholesaler purchases. source
- ProQuad sales decreased 14% in Q2 2026 and increased 10% in the first six months of 2026; U.S. ProQuad sales were previously benefited by a $24 million partial replenishment in Q2 2025 and a net reduction of $49 million to U.S. ProQuad sales for the first six months of 2025 due to borrowing from the CDC Pediatric Vaccine Stockpile. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.4% | Worldwide sales were $16.6 billion and $32.9 billion in the second quarter and first six months of 2026, representing increases of 5%… |
| revenue | positive | realized | +4.8% | Worldwide sales were $16.6 billion and $32.9 billion in the second quarter and first six months of 2026, representing increases of 5%… |
| revenue | negative | realized | -1.3% | Sales of Gardasil/Gardasil 9 were $1,169 million in the three months ended June 30, 2026 and $2,238 million in the six months ended June… |
| revenue | positive | realized | +0.3% | Sales of Gardasil/Gardasil 9 were $1,169 million in the three months ended June 30, 2026 and $2,238 million in the six months ended June… |